Reason for request
Extension of indication
Clinical Benefit
Clinical Added Value
| moderate |
LUCENTIS 10 mg/mL, solution for injection provides a moderate improvement in actual benefit (level III) in terms of efficacy in comparison with VISUDYNE in the treatment of visual impairment due to choroidal neovascularisation secondary to pathologic myopia. |
eNq1mFFv2jAQx9/5FFHeSQgrpZsC1cbaDanVGC3atJfKJEcxc+30bAPdp59D6EonR20Nfkzs/O/i//nnk9PT9R0LloCSCt4Lk6gVBsAzkVN+2wsn1+fNk/C030gXZEmeprXNvChJwiBjRMpeWI5GUyBcRj8vLz6D+R4w7DeCVEwXkKln87SiLPpK5PySFOWcIF0Kmgd3oOYi74WFVpu3QSoVmiz6K4G/ZUEySOPtm93Rxc3R7vs0LsVeoaol4AXht1ZR4E6amUYErgZEwa3Ah5p83zlpUzkGKTRmMCJqPkKxpDnk1hAzwiQ4BZmt8ivAJQNVBrGKx4vsTjqJkwVZj+F+aE/6oxkdqLVqtppJ9+T4OGknnaNuq+MUCneWyu6C+Yk4u0m67VbS7sbAY6YzYx2VjuaMBCrCPNlC5eB5ZXmKg3D/ov05lQUjD9FCFq5LRZCYYUCz//39SPkH12iIxMya/afPNWPxG7OebHnhKeMSRwOhuarBxvnYdSEGgitY1zvqRjq13tYiBXk42T+C2yk/0lNGM1emGepokGoyHtYj7aA0+EQkTNAfDn5QnouVPDxmdm31lH2xIaVVtMA8uWm/PzlOOh3nXfTL1FDNGXOmURQQGwA5OrvlypDPxL5EMWVpl3osysPV46bVERlhUNPsNB3pYgrxsTfzVur+tlE1YBX9cnbtWh/fNeDD1ebRKk3z3j9n3dDrg+emGmsTf3ttV1vcSxus0Y6OuVKF/BDHcyKbkpgVimZ4eK7vnKX+OnAvB3bVwFRs9JT6tDr0Xm+P6xZ76Tjft0Xdfr9tha0xFGrYw4eKxt6YOTw7PIaf+lNvaY+eYcNfmE0vSRQV3FeLo6dWxf3Ab3zl52jg8G02ozW3IbV1mcbVTUy/kcblLUy/8RcvreMz
Lg6ygVydxnBpB4nL
